Literature DB >> 8546899

Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

P Korkolopoulou1, L Kaklamanis, F Pezzella, A L Harris, K C Gatter.   

Abstract

Presentation of endogenous antigenic peptides to cytotoxic T lymphocytes is mediated by the major histocompatibility complex (MHC) class I molecules. For the stable assembly of MHC class I complex it is necessary that the antigenic peptide is transported by the MHC-encoded transporters TAP-1 and TAP-2 into a pre-Golgi region. T-cell-mediated host-vs-tumour response might therefore depend on the presence of these molecules on tumour cells. The presence of MHC class I antigens and TAP-1 was studied in a series of 93 resection specimens of non-small-cell lung carcinomas (NSCLCs) by immunohistochemical methods using antibodies against the assembled class I molecule, beta 2-microglobulin (beta 2-m), heavy-chain A locus, A2 allele and TAP-1 protein. Eighty-six patients were included in the survival analysis. Total loss of class I molecule was observed in 38% of the cases and was usually accompanied by loss of beta 2-m and of heavy chain A locus. Selective loss of A locus was seen in 8.3% and of A2 allele in 27% of the cases. TAP-1 loss was always combined with beta 2-m and/or heavy chain A locus loss. No correlation was found between the expressional status of any of the above molecules, including the selective A2 allelic loss and histological type, degree of differentiation, tumoral stage, nodal stage and survival. Our findings suggest that loss of antigen-presenting molecules (including both MHC class I alleles and TAP-1) is a frequent event in lung cancer. However, the immunophenotypic profile of MHC class I and TAP-1 seems to be unrelated in vivo to the phenotype, growth or survival of NSCLC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8546899      PMCID: PMC2074307          DOI: 10.1038/bjc.1996.28

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  44 in total

1.  Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters.

Authors:  J Trowsdale; I Hanson; I Mockridge; S Beck; A Townsend; A Kelly
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

Review 2.  MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

3.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens.

Authors:  P Parham; C J Barnstable; W F Bodmer
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

4.  The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin.

Authors:  B Arce-Gomez; E A Jones; C J Barnstable; E Solomon; W F Bodmer
Journal:  Tissue Antigens       Date:  1978-02

5.  Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens.

Authors:  F M Brodsky; W F Bodmer; P Parham
Journal:  Eur J Immunol       Date:  1979-07       Impact factor: 5.532

6.  HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy.

Authors:  N J Stam; T M Vroom; P J Peters; E B Pastoors; H L Ploegh
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

7.  Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation.

Authors:  M Redondo; F Ruiz-Cabello; A Concha; T Cabrera; M Pérez-Ayala; M R Oliva; F Garrido
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

8.  Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer.

Authors:  L Kaklamanis; A Townsend; I A Doussis-Anagnostopoulou; N Mortensen; A L Harris; K C Gatter
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

9.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  39 in total

Review 1.  Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Authors:  F Salazar-Onfray
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 2.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Analysis of HLA class Ia transcripts in human leukaemias.

Authors:  Durjoy Majumder; Debasis Bandyopadhyay; Sarmila Chandra; Ashis Mukhopadhayay; Nandini Mukherjee; Subir K Bandyopadhyay; Subrata Banerjee
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

Review 4.  Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Authors:  David P Carbone; David R Gandara; Scott J Antonia; Christoph Zielinski; Luis Paz-Ares
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

5.  Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production.

Authors:  M Urosevic; M O Kurrer; J Kamarashev; B Mueller; W Weder; G Burg; R A Stahel; R Dummer; A Trojan
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

6.  Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines.

Authors:  H Pandha; A Rigg; J John; N Lemoine
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

7.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.

Authors:  T Kageshita; S Hirai; T Ono; D J Hicklin; S Ferrone
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

8.  Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.

Authors:  Wen-Chin Huang; Jonathan J Havel; Haiyen E Zhau; Wei Ping Qian; Hui-Wen Lue; Chia-Yi Chu; Takeo Nomura; Leland W K Chung
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

9.  Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.

Authors:  Renzo G DiNatale; A Ari Hakimi; Timothy A Chan
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

Review 10.  TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.

Authors:  Khalil Choucair; Susan Morand; Laura Stanbery; Gerald Edelman; Lance Dworkin; John Nemunaitis
Journal:  Cancer Gene Ther       Date:  2020-04-28       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.